N,N-dimethyl-6-(2-propen-1-yl)-4H-imidazo[5,1-c][1,4]benzoxazin-3-carboxamide | 876921-21-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-dimethyl-6-(2-propen-1-yl)-4H-imidazo[5,1-c][1,4]benzoxazin-3-carboxamide
• 英文别名: N,N-dimethyl-6-(2-propen-1-yl)-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide；N,N-Dimethyl-6-(2-propen-1-yl)-4H-imidazo[5,1-c][1,4]-benzoxazine-3-carboxamide；N,N-dimethyl-6-prop-2-enyl-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide
• CAS: 876921-21-0
• 化学式: C₁₆H₁₇N₃O₂
• 分子量: 283.33
• InChiKey: JHTUGPXAZHDULV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-6-(2-propen-1-yl)-4H-imidazo[5,1-c][1,4]benzoxazin-3-carboxamide 在 四氧化锇 、 N-甲基吗啉氧化物 作用下， 以 水 、 丙酮 为溶剂， 反应 4.0h， 以60%的产率得到6-(2,3-dihydroxypropyl)-N,N-dimethyl-4H-imidazo[5,1-c][1,4]benzoxazin-3-carboxamide
  参考文献：
  名称：

  [EN] FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS
  [FR] DERIVES TRICYCLIQUES ACCOLES POUR LE TRAITEMENT DE TROUBLES PSYCHOTIQUES

  摘要：

  式中R1、R2、X、A、Y、B、Z1、Q、p、r和s在说明书中定义的用于治疗精神疾病、抑郁障碍、焦虑障碍和性功能障碍的(I)式化合物。

  公开号：

  WO2006024517A1
• 作为产物：
  描述：

  6-(2-propen-1-yl)-4H-imidazo[5,1-c][1,4]benzoxazin-3-carboxylic acid 、 二甲胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以41%的产率得到N,N-dimethyl-6-(2-propen-1-yl)-4H-imidazo[5,1-c][1,4]benzoxazin-3-carboxamide
  参考文献：
  名称：

  [EN] FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS
  [FR] DERIVES TRICYCLIQUES ACCOLES POUR LE TRAITEMENT DE TROUBLES PSYCHOTIQUES

  摘要：

  式中R1、R2、X、A、Y、B、Z1、Q、p、r和s在说明书中定义的用于治疗精神疾病、抑郁障碍、焦虑障碍和性功能障碍的(I)式化合物。

  公开号：

  WO2006024517A1

文献信息

• [EN] FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] DERIVES TRICYCLIQUES ACCOLES POUR LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2006024517A1

  公开（公告）日：2006-03-09

  Compounds of formula (I) wherein R1, R2, X, A, Y, B, Z1, Q, p, r and s are defined in the specification for treating inter alia psychotic disorders, depressive disorders, anxiety disorders and sexual dysfunctions.

  式中R1、R2、X、A、Y、B、Z1、Q、p、r和s在说明书中定义的用于治疗精神疾病、抑郁障碍、焦虑障碍和性功能障碍的(I)式化合物。
• FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS
  申请人：Bentley Jonathan

  公开号：US20120022056A1

  公开（公告）日：2012-01-26

  Compounds of formula (I) wherein R 1 , R 2 , X, A, Y, B, Z 1 , Q, p, r and s are defined in the specification for treating inter alia psychotic disorders, depressive disorders, anxiety disorders and sexual dysfunctions.

  式(I)中的化合物，其中R1、R2、X、A、Y、B、Z1、Q、p、r和s在规范中定义，用于治疗精神疾病、抑郁症、焦虑症和性功能障碍等疾病。
• Design and Synthesis of Novel Tricyclic Benzoxazines as Potent 5-HT_1A/B/D Receptor Antagonists Leading to the Discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4<i>H</i>-imidazo[5,1-<i>c</i>][1,4]benzoxazine-3-carboxamide (GSK588045)
  作者：Steven M. Bromidge、Roberto Arban、Barbara Bertani、Silvia Bison、Manuela Borriello、Paolo Cavanni、Giovanna Dal Forno、Romano Di-Fabio、Daniele Donati、Stefano Fontana、Massimo Gianotti、Laurie J. Gordon、Enrica Granci、Colin P. Leslie、Luca Moccia、Alessandra Pasquarello、Ilaria Sartori、Anna Sava、Jeannette M. Watson、Angela Worby、Laura Zonzini、Valeria Zucchelli

  DOI：10.1021/jm100482n

  日期：2010.8.12

  Bioisoteric replacement of the metabolically labile N-methyl amide group of a series of benzoxazinones with small heterocyclic rings has led to novel series of fused tricyclic benzoxazines which are potent 5-HT1A/B/D receptor antagonists with and without concomitant human serotonin transporter (hSerT) activity. Optimizing against multiple parameters in parallel identified 6-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045) as a potent 5-HT1A/B/D receptor antagonist with a high degree of selectivity over human ether-a-go-go related gene (hERG) potassium channels, favorable pharmacokinetics, and excellent activity in vivo in rodent pharmacodynamic (PD) models. On the basis of its outstanding overall profile, this compound was progressed as a clinical candidate with the ultimate aim to assess its potential as a faster acting antidepressant/anxiolytic with reduced side-effect burden.